How does pancreatic cancer develop? Imlications for treatment
|
|
|
- Carol Norman
- 5 years ago
- Views:
Transcription
1 How does pancreatic cancer develop? Imlications for treatment Roland M. Schmid II. Medizinische Klinik, Klinikum rechts der Isar Technische Universität München FALK Symposium 150, October 3 4, 2005 Berlin
2 Pancreatic cancer early diagnosis of ductal adenocarcinoma is rare at diagnosis % of cancers are resectable, < 1 % curable wide resection is impossible perineural infiltration, early metastasis to lymph nodes, peritoneum and liver ductal phenotype, intense desmoplastic reaction no sensitivity to chemotherapy or radiotherapy
3 How does pancreatic cancer develop? Environmental / genetic causes? Genetic alterations in pancreatic cancer specimens? Precancerous lesions? Molecular mechanisms of initition of carcinogenesis? Cell of origin of pancreatic cancer? Genetic pathways to pancreatic cancer developement? Epigenetic changes? Mechanisms of metastasis?
4 How does pancreatic cancer develop? Environmental / genetic causes? Genetic alterations in pancreatic cancer specimens? Precancerous lesions? Molecular mechanisms of initition of carcinogenesis? Cell of origin of pancreatic cancer? Genetic pathways to pancreatic cancer developement? Epigenetic changes? Mechanisms of metastasis?
5 How does pancreatic cancer develop? Textbook genetic 10 % smooking 30 % nutrition 20 % benign diseases 4 % unknown 36 %
6 How does pancreatic cancer develop? start of disease neoplasia invasion metastasis birth death
7 How does pancreatic cancer develop? environment start of disease neoplasia invasion metastasis birth death
8 How does pancreatic cancer develop? smoking / obesity start of disease neoplasia invasion metastasis birth death
9 How does pancreatic cancer develop? environment start of disease neoplasia invasion metastasis birth death genetic predisposition
10 Genetic predisposition - monogenic diseases FAMMM Peutz-Jeghers syndrome FAP HNPCC BRCA2-associated carcinoma Ataxia teleangiectasia Li-Fraumeni syndrome Hereditary pancreatitis CDKN2 (p16) STK11 (LKB1) APC MSH2, MLH1 BRCA2 ATM TP53 (p53) PRSS1
11 Genetic predisposition family history FAMMM Peutz-Jeghers syndrome FAP HNPCC BRCA2-associated carcinoma Ataxia teleangiectasia Li-Fraumeni syndrome Hereditary pancreatitis Familial pancreatic cancer CDKN2 (p16) STK11 (LKB1) APC MSH2, MLH1 BRCA2 ATM TP53 (p53) PRSS1
12 Familial pancreatic cancer Carter Family PaCa PaCa, BreastCa PaCa PaCa PaCa Jimmy Carter
13 Familial pancreatic cancer 5-fold increased risk with 2 first degree relatives with pancreatic cancer 18-fold increased risk with > 2 first degree relatives with pancreatic cacner 57-fold increased risk with > 3 first degree relatives with pancreatic cancer Tersmette et al 2001, Ghardirian et al 2002
14 How does pancreatic cancer develop? environment start of disease neoplasia invasion metastasis birth death monogenic/ polygenic
15 Risik groups pancreatic cancer risik age 57 >3 relatives hered. pancr >2 relatives chronic pancreatitis 61 5 >1 relatives 65 2,7 obesity 66 2 smoking Rulyak et al 2003, Klein et al 2002, Tersmette et al 2001
16 How does pancreatic cancer develop? smoking start of disease neoplasia invasion metastasis birth death family history
17 Risik groups pancreatic cancer risik age > >2 relatives smoking , Rulyak et al 2003, Klein et al 2002, Tersmette et al 2001
18 How does pancreatic cancer develop? Environmental / genetic causes? Genetic alterations in pancreatic cancer specimens? Precancerous lesions? Molecular mechanisms of initition of carcinogenesis? Cell of origin of pancreatic cancer? Genetic pathways to pancreatic cancer developement? Epigenetic changes? Mechanisms of metastasis?
19 How does pancreatic cancer develop? diagnosis: resectable pancreatic cancer start of disease neoplasia invasion birth Whippel
20 Structural changes in pancreatic cancer specimens KRAS mutations 100 % INK4a (p16) inactivation 82 % Tp53 (p53) inactivated 76 % SMAD4 (DPC4) inactivated 53 % Rozenblum E et al 1997
21 Tumo-suppressive pathways in Pancreatic cancer KRAS mutations 38 additional tumor suppressor p16, p53, and DPC4 inactivation 15 3x p16 and p53 inactivated 10 p16 and DPC4 inactivated 5 2x p53 and DPC4 inactivated 0 only p53 inactivated 4 only p16 inactivated 2 1x only DPC4 inactivated 0 wild-type p16, p53, and DPC4 2 Rozenblum E et al 1997
22 How does pancreatic cancer develop? Environmental / genetic causes? Genetic alterations in pancreatic cancer specimens? Precancerous lesions? Molecular mechanisms of initition of carcinogenesis? Cell of origin of pancreatic cancer? Genetic pathways to pancreatic cancer developement? Epigenetic changes? Mechanisms of metastasis?
23 How does pancreatic cancer develop? start of disease neoplasia invasion birth?
24 PanIN-IA
25 PanIN-IB
26 PanIN-II
27 PanIN-III
28 Genetic alteration in PanINs PanIN-1A PanIN-1B PanIN-2 PanIN-3 Pancreatic Intraepithelial Neoplasia
29 Genetic alteration in PanINs PanIN-1A PanIN-1B PanIN-2 PanIN-3 telomeric length KRAS CDKN2/INK4A (p16) TP53 (p53) PanIN-3 is genetically advanced SMAD4 (DPC4)
30 Genetic alteration in PanINs PanIN-1A PanIN-1B PanIN-2 PanIN-3 expression changes (screened 21329) pancreatic cancer: 610 expression changes PanIN-2 is the ealiest truely preneoplastic lesions Buchholz et al 2005
31 How does pancreatic cancer develop? start of disease neoplasia invasion birth PanINs 50 % at the age of 50 habor PanIN-1B lesions
32 How does pancreatic cancer develop? Environmental / genetic causes? Genetic alterations in pancreatic cancer specimens? Precancerous lesions? Molecular mechanisms of initition of carcinogenesis? Cell of origin of pancreatic cancer? Genetic pathways to pancreatic cancer developement? Epigenetic changes? Mechanisms of metastasis?
33 How does pancreatic cancer develop? start of disease neoplasia invasion birth Kras?
34 Pancreatic development organspecification stem cell Progenitor cell differentated cell PDX-1 Ptf1 PDX-1 endocrine ductal (Ptf1a = p48) Ptf1 exocrine
35 Pancreatic cancer development organspecification stem cell progenitor cell differentated cell PDX-1 Ptf1 PDX-1 endocrine ductal pancreatic cancer cell ductal (Ptf1a = p48) Ptf1 exocrine
36 Expression of Kras G12V in CK19 positive cells differentated cell endocrine CK19 Kras G12V? ductal exocrine
37 Expression of Kras G12V in CK19 positive cells A A: wild type B: CK19-Kras G12V C: anti-cd4 D: ductal hyperplasia Brembeck et al 2003
38 Expression of Kras G12V in CK19 positive cells differentated cell endocrine ductal CK19 Kras G12V no PanINs no tumors infiltration with CD4 + lymphocytes exocrine
39 Expression of Kras G12D in elastase positive cells differentated cell endocrine ductal CK19 Kras G12V no PanINs no tumors infiltration with CD4 + lymphocytes exocrine elastase Kras G12D?
40 Expression of Kras G12D in elastase positive cells D: hyperplastic acini E: tubular complexes, increased stroma K: 16 months old, intraductal papillary mucinous carcinoma (IPMT) M: CK19 Grippo et al 2003
41 Expression of Kras G12D in elastase positive cells differentated cell endocrine ductal exocrine CK19 elastase Kras G12V Kras G12D no PanINs no tumors infiltration with CD4 + lymphocytes no PanINs tubular complexes acinar-to-ductal metaplasia IPMT
42 Activation of Kras G12D in pancreatic stem cells organspecification stem cell PDX-1 Ptf1 Kras G12D? (Ptf1a = p48)
43 Activation of Kras G12D in pancreatic stem cells 1 WT STOP 1* Kras G12D PDX-1-Cre or Ptf1-Cre 1 WT 1* Kras G12D
44 Activation of Kras G12D in pancreatic stem cells control Kras G12D ; PDX-1-Cre K-ras G12D ; Ptf1-Cre 2 months 5 months Hingorani et al 2003
45 Activation of Kras G12D in pancreatic stem cells A: wild type; B: reactive duct; C and D: PanIN-1A; E and F: PanIN-1B Hingorani et al 2003
46 Activation of Kras G12D in pancreatic stem cells G and H: PanIN-2; I to L: PanIN-3 Hingorani et al 2003
47 Activation of Kras G12D in pancreatic stem cells Hingorani et al 2003
48 Activation of Kras G12D in pancreatic stem cells I to K: liver L to N: lung O: lymph node P: diaphragma Q: perineural Hingorani et al 2003
49 Activation of Kras G12D in pancreatic stem cells organspecification stem cell PanIN-1-3 PDX-1 Ptf1 (Ptf1a = p48) Kras G12D ductal pancreatic carcinoma typical metastasis perineural infiltration
50 How does pancreatic cancer develop? Environmental / genetic causes? Genetic alterations in pancreatic cancer specimens? Precancerous lesions? Molecular mechanisms of initition of carcinogenesis? Cell of origin of pancreatic cancer? Genetic pathways to pancreatic cancer developement? Epigenetic changes? Mechanisms of metastasis?
51 Origin of pancreatic cancer organspecification stem cell progenitor cell ductal pancratic cancer cell PDX-1 Ptf1 PDX-1 Kras G12D (Ptf1a = p48) Ptf1
52 Cancer-stem cell hypothesis... mutations convert normal stem-cell selfrenewal pathways into engines for neoplastic proliferation specific gene products regulate both the selfrenewal of normal somatic stem cells and the proliferation of cancer stem cells... Smalley & Ashworth 2003
53 How does pancreatic cancer develop? Environmental / genetic causes? Genetic alterations in pancreatic cancer specimens? Precancerous lesions? Molecular mechanisms of initition of carcinogenesis? Cell of origin of pancreatic cancer? Genetic pathways to pancreatic cancer developement? Epigenetic changes? Mechanisms of metastasis?
54 Genetic alteration in PanINs PanIN-1A PanIN-1B PanIN-2 PanIN-3 telomeric length KRAS CDKN2/INK4A (p16) TP53 (p53) SMAD4 (DPC4)
55 Tumo-suppressive pathways in Pancreatic cancer KRAS mutations 38 additional tumor suppressor p16, p53, and DPC4 inactivation 15 p16 and p53 inactivated 10 p16 and DPC4 inactivated 5 p53 and DPC4 inactivated 0 only p53 inactivated 4 only p16 inactivated 2 only DPC4 inactivated 0 wild-type p16, p53, and DPC4 2 Rozenblum E et al 1997
56 How does pancreatic cancer develop? start of disease neoplasia invasion birth Kras Ink4a?
57 Activation of Kras G12D and inactivation of Ink4a/Arf in pancreatic stem cells organspecification stem cell PDX-1 Ptf1 Kras G12D Ink4a/Arf -/-? (Ptf1a = p48)
58 Activation of Kras G12D and inactivation of Ink4a/Arf in pancreatic stem cells well poorly differentiated differentiated sarcomatoid well poorly differentiated differentiated sarcomatoid Aguirre et al 2003 CK19 CK19 CK19
59 Activation of Kras G12D and inactivation of Ink4a/Arf in pancreatic stem cells A: duodenal invasion B: lymph node metastasis C: invasion in stomach wall D: micrometastasis in the portal tract in the liver E: invasion in the spleen F: E, CK19 Aguirre et al 2003
60 Activation of Kras G12D and inactivation of Ink4a/Arf in pancreatic stem cells GTP-Ras Smad4 p53 Aguirre et al 2003
61 Activation of Kras G12D and inactivation of Ink4a/Arf in pancreatic stem cells organspecification stem cell PanIN-1-3 PDX-1 Ptf1 (Ptf1a = p48) Kras G12D Ink4a/Arf -/- sarcomatoid anaplastic ductal pancreatic carcinoma highly invasive micrometastasis wildtype Tp53 wildtype Smad4
62 Genetic alteration in PanINs PanIN-1A PanIN-1B PanIN-2 PanIN-3 telomeric length KRAS CDKN2/INK4A (p16) TP53 (p53) SMAD4 (DPC4)
63 Tumo-suppressive pathways in Pancreatic cancer KRAS mutations 38 additional tumor suppressor p16, p53, and DPC4 inactivation 15 p16 and p53 inactivated 10 p16 and DPC4 inactivated 5 p53 and DPC4 inactivated 0 only p53 inactivated 4 only p16 inactivated 2 only DPC4 inactivated 0 wild-type p16, p53, and DPC4 2 Rozenblum E et al 1997
64 Activation of Kras G12D and Tp53 R172H in pancreatic stem cells organspecification stem cell PDX-1 Ptf1 Kras G12D Tp53 R172H? (Ptf1a = p48)
65 Acceleration of pancreatic cancer development following activation of Kras G12D and Tp53 R172H in pancreatic stem cells WT Cre Cre, Tp53 R172H K-RAS G12D K-RAS G12D, Tp53 R172H Hingorani et al 2005
66 PDA following activation of Kras G12D and Tp53 R172H in pancreatic stem cells I: PanIN-1a H: PDA (4.5 months) I: liver-met J: ~ CK19 K: lung-met L: ~ CK19 M: PDA (3 months) diff / undiff N: ~ Alcian blue (mucin) O: ~ CK19 Hingorani et al 2005
67 LOH of wild-type Tp53 in PDA C to H: no expression of p53 in PanIN, strong expression in PDA and liver metastasis (H) Hingorani et al 2005
68 Centrosome amplification in pancreatic carcinoma cell lines K-RAS G12D,Tp53 R172H cell lines: primary PDA liver mets K-RAS G12D primary PDA A and C: > 2 centromers B and D: abnormal mitotic spindles Hingorani et al 2005 E: 2 centromers F: normal spindles
69 Non-reciprocal translocations in cell lines of Kras G12D, Tp53 R172H pancreatic tunors SKY-analysis A to C and D to F: non-reciprocal translocations FISH-analysis telomeric signal G: primary duct cells H and I: pancreatic tumor cell line Hingorani et al 2005
70 Chromosomal instability (CIN) in PDA following activation of Kras G12D and Tp53 R172H in pancreatic stem cells G to I: abundant anaphases J: abnormal anaphase K and L: abnormal mitotic figures M and N: nuclear bridges (cell lines) Hingorani et al 2005
71 Retained expression of p16 Ink4a and Smad4(Dpc4) in cell lines of PDA p16 Ink4a Smad4 p53 Hingorani et al 2005
72 Activation of Kras G12D and Tp53 R172H in pancreatic stem cells organspecification stem cell PDX-1 Ptf1 Kras G12D Tp53 R172H PanIN-1-3 ductal pancreatic carcinoma typical (macro)metastasis (Ptf1a = p48) chromosomal instability wildtype p16 wildtype Smad4
73 How does pancreatic cancer develop? start of disease neoplasia invasion metastasis birth Kras G12D Tp53 R172H/-
74 Inactivation of tumor suppressors alters the phenotype of K-ras G12D Kras G12D??? Kras G12D Tp53 R172H CIN glandular makrometastatic PDAC Kras G12D Ink4a/Arf -/- anaplastic/sarcomatoid mikrometastatic PDAC time
75 How does pancreatic cancer develop? Environmental / genetic causes? Genetic alterations in pancreatic cancer specimens? Precancerous lesions? Molecular mechanisms of initition of carcinogenesis? Cell of origin of pancreatic cancer? Genetic pathways to pancreatic cancer developement? Epigenetic changes? Mechanisms of metastasis?
76 TGF-α / EGFR / ErbB2 / RAS - signaling TGF-α BAD PIP 3 PDK1 P PIP 2 EGFR ErbB2 PI3K P P Gr2 SOS RAS RAF Kras G12D Caspase 9 AKT P MEK BAX mtor IKK P IκBα P Erk1/2 nucleus 50 65
77 Expression of Kras G12D in pancreatic stem cells and of TGFα in elastase positive cells organspecification stem cell progenitor cell ductal pancratic cancer cell PDX-1 Ptf1 PDX-1 Kras G12D (Ptf1a = p48) Ptf1 Ela-TGFα
78 Expression of Kras G12D in pancreatic stem cells and of TGFα in elastase positive cells wild-type Ela-TGFα Kras G12D ; Ptf1-Cre Ela-TGFα Siveke et al unpublished
79 TGFα expression increases Ras activity IP IB RBD Ras - Ras wild-type TGFα Kras G12D Kras G12D + TGFα
80 Expression of Kras G12D in pancreatic stem cells and of TGFα in elastase positive cells
81 Expression of Kras G12D in pancreatic stem cells and of TGFα in elastase positive cells
82 Expression of Kras G12D in pancreatic stem cells and of TGFα in elastase positive cells
83 Expression of Kras G12D in pancreatic stem cells and of TGFα in elastase positive cells Amylase Muc5 Muc5 Muc5
84 Expression of Kras G12D in pancreatic stem cells and of TGFα in elastase positive cells BrdU
85 Expression of Kras G12D in pancreatic stem cells and of TGFα in elastase positive cells organspecification stem cell progenitor cell PDX-1 Ptf1 (Ptf1a = p48) Kras G12D PDX-1 Ptf1 Ela-TGFα PanIN-1-3 ductal pancreatic carcinoma IPMT
86 IKK / IκBα / NF-κB - signaling TGF-α BAD PIP 3 PDK1 P PIP 2 EGFR ErbB2 PI3K P P Gr2 SOS RAS RAF Kras G12D Caspase 9 AKT P MEK BAX mtor IKK P IκBα P Erk1/2 nucleus NF-κB Cyclin D Bcl-x L
87 IKK / IκBα / NF-κB - signaling TGF-α BAD PIP 3 PDK1 P PIP 2 EGFR ErbB2 PI3K P P Gr2 SOS RAS RAF Kras G12D Caspase 9 AKT P MEK BAX mtor IKK P IκBα P Erk1/2 nucleus NF-κB Cyclin D Bcl-x L
88 Activation of Kras G12D and inactivation of rela in pancreatic stem cells organspecification stem cell PDX-1 Ptf1 Kras G12D rela -/-? (Ptf1a = p48)
89 Inactivation of rela does not alter Ras activity IP IB RBD Ras - Ras wild-type Kras G12D Kras G12D rela F/F
90 H&E 1 mon Kras G12D/+ Ptfa Cre/+ Kras G12D/+ rela F/F Ptfa Cre/+ 50x 50x 100x 100x
91 H&E 2.25 mon Kras G12D/+ Ptfa Cre/+ Kras G12D/+ rela F/F Ptfa Cre/+ 50x 50x 100x 100x
92 H&E 4.5 mon Kras G12D/+ Ptfa Cre/+ Kras G12D/+ rela F/F Ptfa Cre/+ 50x 50x 100x 100x
93 Trichrom-stain Kras G12D/+ Ptfa Cre/+ Kras G12D/+ rela F/F Ptfa Cre/+ 50x 50x 4.5 mon 2.25 mon 100x 100x
94 4.5 mon Kras G12D/+ Ptfa Cre/+ Kras G12D/+ rela F/F Ptfa Cre/+ 50x 50x Amylase CK x 100x
95 MUC-5 Kras G12D/+ Ptfa Cre/+ Kras G12D/+ rela F/F Ptfa Cre/+ 4,5 Mon 2.25 Mon
96 Activation of Kras G12D and inactivation of rela in pancreatic stem cells organspecification stem cell progression of PanIN-1-3 PDX-1 Ptf1 (Ptf1a = p48) Kras G12D rela -/- loss of acinar cells increased number of CK19 positive cells increased desmoplastic recation
97 How does pancreatic cancer develop? start of disease neoplasia invasion metastasis birth?
98 CXCL12 CXCR4 signaling induces metastasis peripheal blood neutrophils blood vessel wall CXCL12 CXCR4 stroma cells
99 CXCL12 CXCR4 signaling induces metastasis peripheal blood neutrophils tumor cells blood vessel wall CXCL12 CXCR4 CXCR4 CXCL12 metastasis stroma cells
100 Detection of tumor cell growth in vivo day 5 p.i. day 7 p.i. day 10 p.i. day 15 p.i.
101 CXCR4 overexpression induces liver and lung metastasis lung liver lung H&E BrdU CXCR4
102 CXCR4 overexpression induces liver and lung metastasis cell line Tumorigenicity Frequency (metastasis/ total) Lung (metastasis /total) Liver (metastasis/ total) TD-2 fluc 14/14 2/14 2/14 0/14
103 CXCR4 overexpression induces liver and lung metastasis cell line Tumorigenicity Frequency (metastasis/ total) Lung (metastasis /total) Liver (metastasis/ total) TD-2 fluc 14/14 2/14 2/14 0/14 TD-2 fluc CXCR4 14/14 12/14 9/14 4/14
104 CXCR4 overexpression induces liver and lung metastasis cell line Tumorigenicity Frequency (metastasis/ total) Lung (metastasis /total) Liver (metastasis/ total) TD-2 fluc 14/14 2/14 2/14 0/14 TD-2 fluc CXCR4 TD-2 fluc CXCR4 +AMD /14 12/14 9/14 4/14 7/7 1/7 1/7 0/7
105 How does pancreatic cancer develop? start of disease neoplasia invasion metastasis birth CXCR4
106 How does pancreatic cancer develop? environment start of disease PanINs invasion metastasis birth Kras G12D Tp53 R172H/- CXCR4 Ink4a/Arf -/- genetic predisposition
107 Acknowledgement TU München Hana Algül Florian Greten Marina Lesina Hassan Nakhei Dieter Saur Jens Siveke Eric Sandgren David Tuveson
Pancreatic intraepithelial
Pancreatic intraepithelial neoplasia (PanIN) Markéta Hermanová St. Anne s University Hospital Brno Faculty of Medicine, Masaryk University Precursor lesions of invasive pancreatic cancer Pancreatic intraepithelial
Surveillance of Individuals At High Risk For Developing Pancreatic Cancer
Surveillance of Individuals At High Risk For Developing Pancreatic Cancer Marco Bruno Erasmus Medical Center, Rotterdam Pancreatic Cancer Facts & figures One of the most fatal malignancies Overall 5-year
Genetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:
Genetics of Pancreatic Cancer October 6, 2016 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only: 1-408-435-7088
Pancreatobiliary Frozen Section Nightmares
Pancreatobiliary Frozen Section Nightmares Aatur D. Singhi, MD PhD Assistant Professor University of Pittsburgh Medical Center Department of Pathology singhiad@upmc.edu Objectives Briefly give an overview
Biology of cancer development in the GI tract
1 Genesis and progression of GI cancer a genetic disease Colorectal cancer Fearon and Vogelstein proposed a genetic model to explain the stepwise formation of colorectal cancer (CRC) from normal colonic
Colorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.
Colonic Neoplasia Remotti Colorectal adenocarcinoma leading cancer in developed countries In US, annual incidence of colorectal adenocarcinoma 150,000. In US, annual deaths due to colorectal adenocarcinoma
Concomitant Pancreatic Activation of Kras G12D and Tgfa Results in Cystic Papillary Neoplasms Reminiscent of Human IPMN
Article Concomitant Pancreatic Activation of Kras G12D and Tgfa Results in Cystic Papillary Neoplasms Reminiscent of Human IPMN Jens T. Siveke, 1 Henrik Einwächter, 1 Bence Sipos, 2 Clara Lubeseder-Martellato,
Beyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University
Beyond the APC era Alternative pathways to CRC Jeremy R Jass McGill University Outline Limitations of APC model KRAS and serrated polyps CRC and CpG island methylation Serrated pathway to CRC Fusion pathways
A Minute Pancreatic Ductal Adenocarcinoma with Lipomatous Pseudohypertrophy of the Pancreas
CASE REPORT A Minute Pancreatic Ductal Adenocarcinoma with Lipomatous Pseudohypertrophy of the Pancreas Sadanobu Izumi 1, Satoko Nakamura 2, Masaki Tokumo 1, Shohei Mano 2 Departments of 1 Surgery and
Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.
Cancer Biology Chapter 18 Eric J. Hall., Amato Giaccia, Radiobiology for the Radiologist Introduction Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell death)
Select problems in cystic pancreatic lesions
Disclosure Select problems in cystic pancreatic lesions Five Prime Therapeutics shareholder Adicet Bio shareholder Bristol-Meyer Squibb advisory board grace.kim@ucsf.edu Pancreatic cystic lesions Intraductal
Molecular genetics of PDAC
Molecular genetics of PDAC Irene Esposito, Melissa Schlitter Pancreatic pathology: Of mice and men Madrid, December 4-6th 2014 Background: Molecular genetic analysis of DNA from paraffin-embedded PDAC
Adenocarcinoma of the pancreas
Adenocarcinoma of the pancreas SEMINARS IN DIAGNOSTIC PATHOLOGY 31 (2014) 443 451 Ralph H.Hruban, MD, David S. Klimstra, MD Paola Parente Anatomia Patologica Casa Sollievo della Sofferenza San Giovanni
TUMOR-SUPPRESSOR GENES. Molecular Oncology Michael Lea
TUMOR-SUPPRESSOR GENES Molecular Oncology 2011 Michael Lea TUMOR-SUPPRESSOR GENES - Lecture Outline 1. Summary of tumor suppressor genes 2. P53 3. Rb 4. BRCA1 and 2 5. APC and DCC 6. PTEN and PPA2 7. LKB1
Quantification of early stage lesions for loss of p53 should be shown in the main figures.
Reviewer #1 (Remarks to the Author): Expert in prostate cancer The manuscript "Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers" uses a number of novel genetically engineered
Pathology of pancreatic tumors
Review Article Pathology of pancreatic tumors Daniel Sanchez, Wang L. Cheung Department of Pathology, Orlando Health, Orlando, USA Contributions: (I) Conception and design: All authors; (II) Administrative
KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS
UNIVERSITÀ DEGLI STUDI DI PALERMO Scuola di Specializzazione in Biochimica Clinica Direttore Prof. Marcello Ciaccio KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS Loredana Bruno KRAS gene Proto-oncogene
Present State of Gene Diagnosis and Future Prospects
Clinical Medicine: Cancer Present State of Gene Diagnosis and Future Prospects JMAJ 45(3): 118 124, 2002 Eiichi TAHARA Chairman, Hiroshima Cancer Seminar Foundation Abstract: The entire base sequence of
Neoplasias Quisticas del Páncreas
SEAP -Aproximación Práctica a la Patología Gastrointestinal- Madrid, 26 de mayo, 2006 Neoplasias Quisticas del Páncreas Gregory Y. Lauwers, M.D. Director, Service Massachusetts General Hospital Harvard
Serrated Polyps and a Classification of Colorectal Cancer
Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram
Molecular markers in colorectal cancer. Wolfram Jochum
Molecular markers in colorectal cancer Wolfram Jochum Biomarkers in cancer Patient characteristics Tumor tissue Normal cells Serum Body fluids Predisposition Diagnostic marker Specific diagnosis Prognostic
Pancreatic Cytopathology: The Solid Neoplasms
Pancreatic Cytopathology: The Solid Neoplasms Syed Z. Ali, M.D. Professor of Pathology and Radiology Director of Cytopathology The Johns Hopkins Hospital Baltimore, Maryland Pancreatic Cytopathology: Past,
Multistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
Pancreatic Cancer: The ABCs of the AJCC and WHO
Pancreatic Cancer: The ABCs of the AJCC and WHO Aatur D. Singhi, MD PhD Assistant Professor University of Pittsburgh Medical Center Department of Pathology singhiad@upmc.edu Case presentation Objectives
Colon Cancer and Hereditary Cancer Syndromes
Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models
Oncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber
Oncogenes and Tumor Suppressors MCB 5068 November 12, 2013 Jason Weber jweber@dom.wustl.edu Oncogenes & Cancer DNA Tumor Viruses Simian Virus 40 p300 prb p53 Large T Antigen Human Adenovirus p300 E1A
Neoplasia 18 lecture 6. Dr Heyam Awad MD, FRCPath
Neoplasia 18 lecture 6 Dr Heyam Awad MD, FRCPath ILOS 1. understand the role of TGF beta, contact inhibition and APC in tumorigenesis. 2. implement the above knowledge in understanding histopathology reports.
Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
Cancer genetics
Cancer genetics General information about tumorogenesis. Cancer induced by viruses. The role of somatic mutations in cancer production. Oncogenes and Tumor Suppressor Genes (TSG). Hereditary cancer. 1
In vitro modeling of pancreatic duct cell carcinogenesis
In vitro modeling of pancreatic duct cell carcinogenesis by Lisa Leung A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Medical Biophysics University of Toronto
Genetically engineered mouse models of pancreatic adenocarcinoma
MOLECULAR ONCOLOGY 7 (2013) 232e247 available at www.sciencedirect.com www.elsevier.com/locate/molonc Review Genetically engineered mouse models of pancreatic adenocarcinoma Carmen Guerra*, Mariano Barbacid*
Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas.
Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition Procedures Cytology (No Accompanying Checklist)
Cancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz
Cancer and Oncogenes Bioscience in the 21 st Century Linda Lowe-Krentz December 1, 2010 Just a Few Numbers Becoming Cancer Genetic Defects Drugs Our friends and family 25 More mutations as 20 you get older
Epidemiology and genetics of pancreatic cancer
1 Epidemiology and genetics of pancreatic cancer Srinivasa K. R. Prasad and Rong Zeng Introduction Pancreatic ductal adenocarcinoma (and its histological variants), also referred to as pancreatic cancer
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
Development of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma
Research article Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma Hideaki Ijichi, 1 Anna Chytil, 2,3 Agnieszka E. Gorska,
Recent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
Department of Pathology and Laboratory Medicine, Brown University School of Medicine, Providence, RI
[Frontiers in Bioscience 3, d1148-1160, November 15, 1998] MOLECULAR PATHOBIOLOGY OF PANCREATIC ADENOCARCINOMA Shamlal Mangray and Thomas C King Department of Pathology and Laboratory Medicine, Brown University
Pancreas composed of 2 parts: 1- exocrine gland 2- endocrine gland
pancreas Pancreas composed of 2 parts: 1- exocrine gland 2- endocrine gland Acute pancreatitis Inflammation of the pancreas associated with acinar cell injury Clinical features: 1-abdominal pain cardinal
Genetic testing and pancreatic disease
Genetic testing and pancreatic disease February 2 d, 2018 Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director,
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
Pancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/6/2018 UpToDate: Liposomal irinotecan (Onivyde) plus FU/LV is now approved for gemcitabine-refractory metastatic pancreatic cancer and recommended by
Invited Re vie W. Molecular genetics of ovarian carcinomas. Histology and Histo pathology
Histol Histopathol (1 999) 14: 269-277 http://www.ehu.es/histol-histopathol Histology and Histo pathology Invited Re vie W Molecular genetics of ovarian carcinomas J. Diebold Pathological Institute, Ludwig-Maximilians-University
Rath, N., and Olson, M. (2016) Regulation of pancreatic cancer aggressiveness by stromal stiffening. Nature Medicine, 22(5), pp. 462-463. There may be differences between this version and the published
Chapt 15: Molecular Genetics of Cell Cycle and Cancer
Chapt 15: Molecular Genetics of Cell Cycle and Cancer Student Learning Outcomes: Describe the cell cycle: steps taken by a cell to duplicate itself = cell division; Interphase (G1, S and G2), Mitosis.
Dr Rodney Itaki Lecturer Anatomical Pathology Discipline. University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology
Neoplasia Dr Rodney Itaki Lecturer Anatomical Pathology Discipline University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Considerations Overview: Neoplasia uncontrolled,
Basement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
Human Lung Cancer Pathology and Cellular Biology Mouse Lung Tumor Workshop
Human Lung Cancer Pathology and Cellular Biology Mouse Lung Tumor Workshop Jan 7 th and 8 th, 2014 Brigitte Gomperts, MD University of California, Los Angeles Lung Structure and Function Airway Epithelial
Familial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
Cancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz October 11, 2013
Cancer and Oncogenes Bioscience in the 21 st Century Linda Lowe-Krentz October 11, 2013 Just a Few Numbers Becoming Cancer Genetic Defects Drugs Our friends and family 200 180 160 140 120 100 80 60 40
Hereditary Gastric Cancer
Hereditary Gastric Cancer Dr Bastiaan de Boer Consultant Pathologist Department of Anatomical Pathology PathWest Laboratory Medicine, QE II Medical Centre Clinical Associate Professor School of Pathology
Falk Symposium No :30-9:00 am, Saturday, October 1, 2005 Maritim Hotel, Berlin Of mice and man: Mouse models for colon carcinogenesis
Falk Symposium No. 149 8:30-9:00 am, Saturday, October 1, 2005 Maritim Hotel, Berlin Of mice and man: Mouse models for colon carcinogenesis Makoto Mark Taketo, M.D., Ph.D. Department of Pharmacology, Graduate
Pancreas Cancer Genomics
Pancreas Cancer Genomics Steven Gallinger MD, MSc, FRCS HPB Surgical Oncology Program University Health Network Samuel Lunenfeld Research Institute Mount Sinai Hospital University of Toronto Fate of the
Enterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Update of mixed tumours of the GI tract, the pancreas and the liver Introduction to the concept of mixed tumours and clinical implication Jean-Yves SCOAZEC Surgical
Lung Neoplasia II Resection specimens Pathobasic. Lukas Bubendorf Pathology
Lung Neoplasia II Resection specimens Pathobasic Lukas Bubendorf Pathology Agenda Preneoplastic lesions Histological subtypes of lung cancer Histological patterns of AC Cells of origin and characteristic
5/21/2018. An Update on Pancreas Neoplasms. Arief Suriawinata, M.D. Lines of Differentiation in Pancreatic Neoplasms
An Update on Pancreas Neoplasms Arief Suriawinata, M.D. Professor of Pathology and Laboratory Medicine Geisel School of Medicine at Dartmouth Department of Pathology and Laboratory Medicine Dartmouth-Hitchcock
Familial and Hereditary Colon Cancer
Familial and Hereditary Colon Cancer Aasma Shaukat, MD, MPH, FACG, FASGE, FACP GI Section Chief, Minneapolis VAMC Associate Professor, Division of Gastroenterology, Department of Medicine, University of
Evolution at Its Worst: Cancer. SHP-Neurobiology of Development and Disease
Evolution at Its Worst: Cancer SHP-Neurobiology of Development and Disease Introduction to Cancer Cancer is currently the second leading cause of death in the US (22.8%) behind heart disease. Yearly 0.5%
11/18/2015. Gloria Su, Ph.D. Path G4500. Cancer Statistics 2015 (Siegel et al, CA Cancer J CLIN 2015) The Pancreatic Cancer Burden
Mouse Modeling for Human Pancreatic Cancer Gloria Su, Ph.D. gs2157@columbia.edu, ICRC 10-04 Associate Professor Departments of Pathology and Otolaryngology/Head and Neck Surgery Columbia University College
PANCREAS DUCTAL ADENOCARCINOMA PDAC
CONTENTS PANCREAS DUCTAL ADENOCARCINOMA PDAC I. What is the pancreas? II. III. IV. What is pancreas cancer? What is the epidemiology of Pancreatic Ductal Adenocarcinoma (PDAC)? What are the risk factors
Cell cycle, signaling to cell cycle, and molecular basis of oncogenesis
Cell cycle, signaling to cell cycle, and molecular basis of oncogenesis MUDr. Jiří Vachtenheim, CSc. CELL CYCLE - SUMMARY Basic terminology: Cyclins conserved proteins with homologous regions; their cellular
Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
AP VP DLP H&E. p-akt DLP
A B AP VP DLP H&E AP AP VP DLP p-akt wild-type prostate PTEN-null prostate Supplementary Fig. 1. Targeted deletion of PTEN in prostate epithelium resulted in HG-PIN in all three lobes. (A) The anatomy
LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
BREAST PATHOLOGY. Fibrocystic Changes
BREAST PATHOLOGY Lesions of the breast are very common, and they present as palpable, sometimes painful, nodules or masses. Most of these lesions are benign. Breast cancer is the 2 nd most common cause
Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of
Tiền liệt tuyến Tiền liệt tuyến Gross appearance of nodular hyperplasia in material obtained from suprapubic prostatectomy. Note the multinodular appearance and the admixture of solid and microcystic areas.
THE MECHANISM OF TUMORIGENESIS IN THE IMMORTALIZED HUMAN PANCREATIC CELL LINES: CELL CULTURE MODELS OF HUMAN PANCREATIC CANCER
Texas Medical Center Library DigitalCommons@TMC UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 8-2011 THE MECHANISM OF TUMORIGENESIS IN THE IMMORTALIZED HUMAN PANCREATIC
Trp53 R172H and Kras G12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
Trp53 R172H and Kras G12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice Sunil R. Hingorani, 1,2, * Lifu Wang, 2 Asha S. Multani, 4 Chelsea
Oncogenes and Tumor. supressors
Oncogenes and Tumor supressors From history to therapeutics Serge ROCHE Neoplastic transformation TUMOR SURESSOR ONCOGENE ONCOGENES History 1911 1960 1980 2001 Transforming retrovirus RSV v-src is an oncogene
Colonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern
Colonic polyps and colon cancer Andrew Macpherson Director of Gastroentology University of Bern Improtance of the problem of colon cancers - Epidemiology Lifetime risk 5% Incidence/10 5 /annum (US Detroit
CELL CYCLE REGULATION AND CANCER. Cellular Reproduction II
CELL CYCLE REGULATION AND CANCER Cellular Reproduction II THE CELL CYCLE Interphase G1- gap phase 1- cell grows and develops S- DNA synthesis phase- cell replicates each chromosome G2- gap phase 2- cell
p53 expression in invasive pancreatic adenocarcinoma and precursor lesions
Malaysian J Pathol 2011; 33(2) : 89 94 ORIGINAL ARTICLE p53 expression in invasive pancreatic adenocarcinoma and precursor lesions NORFADZILAH MY MBBCH,* Jayalakshmi PAILOOR MPath, FRCPath,* RETNESWARI
Clinical Cancer Genetics
Clinical Cancer Genetics Lisen Axell, MS, CGC University of Colorado Cancer Center Individuals with cancer Making surgical decisions (lump vs. mast) Making treatment decisions (XRT) Concerns for additional
Plasma-Seq conducted with blood from male individuals without cancer.
Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer
Myriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
Intrahepatic cholangiocarcinoma Histologic spectrum, novel markers and molecular assays
2018 Current Issues in Surgical Pathology Summary (not actual lecture) Intrahepatic cholangiocarcinoma Histologic spectrum, novel markers and molecular assays Sanjay Kakar, MD University of California,
Colorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital
Colorectal Cancer - Working in Partnership David Baty Genetics, Ninewells Hospital Genetics and Pathology National initiatives Colorectal cancer Inherited CRC Sporadic CRC The Liquid Biopsy The future?
Identification of Sox9-Dependent Acinar-to-Ductal Reprogramming as the Principal Mechanism for Initiation of Pancreatic Ductal Adenocarcinoma
Article Identification of Sox9-Dependent Acinar-to-Ductal Reprogramming as the Principal Mechanism for Initiation of Pancreatic Ductal Adenocarcinoma Janel L. Kopp, 1,6 Guido von Figura, 2,6 Erin Mayes,
BIOLOGY OF CANCER. Definition: Cancer. Why is it Important to Understand the Biology of Cancer? Regulation of the Cell Cycle 2/13/2015
BIOLOGY OF CANCER Why is it Important to Understand the Biology of Cancer? Cynthia Smith, RN, BA, MSN, AOCN Oncology Clinical Nurse Specialist Harrison Medical Center Definition: Cancer Regulation of the
The roles of FOXM1 in pancreatic stem cells and carcinogenesis
Quan et al. Molecular Cancer 2013, 12:159 REVIEW The roles of FOXM1 in pancreatic stem cells and carcinogenesis Ming Quan 1,3, Peipei Wang 2, Jiujie Cui 1,3, Yong Gao 2 and Keping Xie 3* Open Access Abstract
Next generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
Triple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
Marcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari
Marcatori biomolecolari dei carcinomi del colon-retto sporadici ed ereditari Milo Frattini XII Congresso AIFEG Villa Cagnola - Gazzada Schianno (VA) 16/17.10.2014 APC β-catenina APC Met (p16) Models of
Supplemental Figures. Amylase. Glucose. Pancreas FAP-WT FAP-KO weight (g) mg/dl U/L 0.
Supplemental Figures A.2 3.1 2 2 1 1.5. 3 U/L 4 mg/dl weight (g).25.15 Amylase Glucose Pancreas B Trichrome HABP PAS H&E Supplemental Figure 1. FAP is dispensable for pancreatic development. (A) The pancreas
CLINICAL SIGNIFICANCE OF BENIGN EPITHELIAL CHANGES
Papillomas. Papillomas are composed of multiple branching fibrovascular cores, each having a connective tissue axis lined by luminal and myoepithelial cells ( Fig. 23-11 ). Growth occurs within a dilated
Molecular pathogenesis of lung cancer
Molecular pathogenesis of lung cancer Pr. Elisabeth Brambilla INSERM U823 Department of Pathology CHU Grenoble France Lung epithelial cells Carcinogen exposure genetic predisposition Auto- and paracrine
Combatting Pancreatic Cancer: Keys to Early Recognition and Diagnosis
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/combatting-pancreatic-cancer-keys-earlyrecognition-and-diagnosis/7286/
Hereditary Aspects of Pancreatic Cancer
Pancreatic Cancer Seminar San Francisco, CA Hereditary Aspects of Pancreatic Cancer Genetic Risk Assessment and Counseling for Familial Pancreatic Cancer February 3, 2016 Amie Blanco, MS, CGC Gordon and
The Hallmarks of Cancer
The Hallmarks of Cancer Theresa L. Hodin, Ph.D. Clinical Research Services Theresa.Hodin@RoswellPark.org Hippocrates Cancer surgery, circa 1689 Cancer Surgery Today 1971: Nixon declares War on Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
Evaluation of hereditary syndromes that include pancreatic cancer
Evaluation of hereditary syndromes that include pancreatic cancer UPR CCC 04/12/13 Jeffrey N. Weitzel, M.D. Chief, Division of Clinical Cancer Genetics Cancer Screening & Prevention Program City of Hope
oncogenes-and- tumour-suppressor-genes)
Special topics in tumor biochemistry oncogenes-and- tumour-suppressor-genes) Speaker: Prof. Jiunn-Jye Chuu E-Mail: jjchuu@mail.stust.edu.tw Genetic Basis of Cancer Cancer-causing mutations Disease of aging
Family history of pancreatic cancer
Family history of pancreatic cancer _ This fact sheet is for people who want to find out about the hereditary risk of pancreatic cancer. You can speak to our specialist nurses on our Support Line about
of 20 to 80 and subsequently declines [2].
![of 20 to 80 and subsequently declines [2].](/thumbs/80/81450506.jpg "of 20 to 80 and subsequently declines [2].")
- - According to the 2014 World Health Organization (WHO) classification and tumor morphology, primary ovarian tumors are subdivided into three categories: epithelial (60%), germ cell (30%), and sex-cord
Nature Medicine: doi: /nm.3559
Supplementary Note 1. A sample alteration report. Each alteration nominated by PHIAL is curated to answer specific fields that are intended to guide physician interpretation. Gene Alteration Patient ID
BRCA and Pancreatic Cancer
BRCA and Pancreatic Cancer Mokenge (Mo) P. Malafa, MD Chair, Department of GI Oncology Program Leader, GI Tumor Program Head, Pancreatic Tumor Section Moffitt Cancer Center Tampa, Florida Objectives What
Pancreatic Cystic Lesions 원자력병원
Pancreatic Cystic Lesions 원자력병원 박선 후 Lines of cellular differentiation Ductal Acinar Undetermined Ductal adenocarcinoma Serous/ mucinous tumor Intraductal papillary mucinous neoplasm Acinar cell carcinoma
Lung tumors & pleural lesions
Lung tumors & pleural lesions A brief introduction 95% of lung tumors are carcinomas Among the remaining 5%, we will discuss: -Hamartoma the most common benign lung tumor spherical, coin lesion on x-rays